Apogee Therapeutics’ (APGE) Buy Rating Reiterated at BTIG Research

Apogee Therapeutics (NASDAQ:APGE)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $137.00 target price on the stock. BTIG Research’s price objective would indicate a potential upside of 70.03% from the company’s previous close.

A number of other analysts also recently issued reports on APGE. Deutsche Bank Aktiengesellschaft initiated coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price for the company. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. Citigroup reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Sunday, January 25th. Wall Street Zen lowered Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Craig Hallum restated a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Apogee Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $103.92.

Apogee Therapeutics Stock Performance

APGE traded up $14.54 during midday trading on Monday, reaching $80.58. The company had a trading volume of 1,844,019 shares, compared to its average volume of 992,418. The stock has a market cap of $5.60 billion, a PE ratio of -19.13 and a beta of 1.39. Apogee Therapeutics has a 12-month low of $26.20 and a 12-month high of $84.56. The business has a 50-day moving average price of $71.25 and a two-hundred day moving average price of $63.40.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.02. On average, research analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the sale, the chief executive officer directly owned 1,152,987 shares in the company, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total value of $133,525,000.00. Following the sale, the director owned 298,647 shares in the company, valued at approximately $22,786,766.10. The trade was a 85.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,839,700 shares of company stock worth $140,118,083 over the last 90 days. Corporate insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after buying an additional 694 shares during the period. Millennium Management LLC boosted its position in shares of Apogee Therapeutics by 100.0% in the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after acquiring an additional 130,164 shares during the period. Creative Planning purchased a new position in Apogee Therapeutics during the second quarter valued at approximately $392,000. Handelsbanken Fonder AB grew its stake in Apogee Therapeutics by 13.3% during the second quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock valued at $369,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Apogee Therapeutics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after acquiring an additional 1,907 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics News Summary

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Phase 2 Part A (APEX) 52‑week data showed durable maintenance and deepening of responses for zumilokibart with both every‑3‑month and every‑6‑month dosing — including 75% and 85% of patients maintaining EASI‑75, and 86% and 78% maintaining vIGA 0/1 — supporting efficacy and an attractive infrequent‑dosing profile. Apogee Therapeutics Announces Positive Phase 2 Part A 52‑Week Data
• Positive Sentiment: Financial and news outlets are reporting the positive readout and attributing the stock move to the data, increasing investor attention and trading volume. Coverage highlights the durable responses and convenience of 3‑ and 6‑month dosing. Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
• Positive Sentiment: Apogee scheduled a conference call/webcast to present the Part A 52‑week results (held March 23), providing management commentary and Q&A that can clarify safety, responder durability, and next steps — a potential near‑term catalyst for guidance or program timing. Apogee Therapeutics to Host Conference Call
• Neutral Sentiment: Analysts and commentators are re‑examining valuation after recent share weakness; while the data de‑risks the program, Apogee remains a clinical‑stage biotech with no commercial revenue — valuation and upside will depend on Phase 2 Part B, safety details, and regulatory path. A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.